Exicure (NASDAQ:XCUR) Issues Quarterly Earnings Results, Beats Expectations By $18.42 EPS

Exicure (NASDAQ:XCUR) released its earnings results on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.42, FiscalAI reports.

Exicure Stock Down 4.6%

NASDAQ:XCUR traded down $0.06 during trading hours on Friday, reaching $1.25. The company had a trading volume of 21,837 shares, compared to its average volume of 84,952. The firm has a market capitalization of $7.96 million, a PE ratio of -0.81 and a beta of 3.65. Exicure has a one year low of $1.18 and a one year high of $9.48. The stock has a 50-day moving average of $1.96 and a two-hundred day moving average of $3.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.